Singapore markets close in 1 hour 41 minutes

Zentalis Pharmaceuticals, Inc. (ZNTL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
10.61+0.17 (+1.63%)
At close: 04:00PM EST
10.10 -0.51 (-4.81%)
After hours: 05:15PM EST
Full screen
Trade prices are not sourced from all markets
Previous close10.44
Open10.59
Bid0.00 x 1300
Ask0.00 x 900
Day's range10.50 - 11.14
52-week range9.56 - 31.46
Volume458,819
Avg. volume1,063,925
Market cap750.825M
Beta (5Y monthly)1.90
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen

    Investor call to be held on Friday, November 10th, at 10:00 a.m. ET Company also to participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15th, 2023 at 8:30 a.m. GMT NEW YORK and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, toda

  • GlobeNewswire

    Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

    Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on track for first NDA submission in a gynecologic malignancy in 2026 Sharing key clinical milestones through 2026 for azenosertib and ZN-d5 $517 million cash balance as of September 30, 2023, with projected cash runway into 2026 Chief Translational Officer, Mark Lackner, Ph.D., to succeed Co-Founder, K

  • GlobeNewswire

    Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEW YORK and SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on November 1, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 271,000 shares of the Company’s common stock to five